Idarubicin Combined to Azacitidine in Int-2 or High Risk Myelodysplastic Syndromes
Condition(s):High Grade Myelodysplastic Syndrome LesionsLast Updated:June 7, 2017Completed
Hide Studies Not Open or Pending
Condition(s):High Grade Myelodysplastic Syndrome LesionsLast Updated:June 7, 2017Completed
Condition(s):Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory Anemia With Excess Blasts in Transformation; Secondary Myelodysplastic SyndromeLast Updated:October 6, 2022Completed
Condition(s):Acute Myeloid Leukemia or Myelodysplastic SyndromesLast Updated:March 26, 2024Completed
Condition(s):Acute Myeloid Leukemia; Myelodysplastic SyndromesLast Updated:May 24, 2023Recruiting
Condition(s):Myelodysplastic SyndromeLast Updated:November 20, 2015Unknown status
Condition(s):Myelodysplastic Syndrome; Leukemia, Myelomonocytic, JuvenileLast Updated:July 11, 2019Completed
Condition(s):Myelodysplastic Syndromes; Myeloproliferative Neoplasm; Acute Myeloid LeukemiaLast Updated:August 11, 2021Completed
Condition(s):Myelodysplastic Syndrome; Acute Myelogenous LeukemiaLast Updated:March 16, 2012Unknown status
Condition(s):Myeloid MalignancyLast Updated:January 5, 2024Recruiting
Condition(s):Squamous Cell Carcinoma of Head and NeckLast Updated:October 19, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.